Free Newsletter
Forbes digs into 'Pfizer's Nigerian nightmare'
As Pfizer negotiates a settlement with the Nigerian government in the long-running dispute over the Trovan drug trial there--and a U.S. federal appeals court considers whether Nigerian plaintiffs can sue the drugmaker here--Forbes delves into the background of the case, looking at documents and interviewing Pfizer officials, victims' families, and the FDA. An "unsettling look at the pitfalls of doing hurried drug trials in Third World countries," the story could be a cautionary tale for drugmakers conducting an increasing amount of research in the developing world. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: